BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsFinancing

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”)

Related news

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

PRQRProQR Therapeutics2026-06-25 10:35 EST

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

OTLKOutlook2026-08-13 01:45 EST

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

KPRXKiora Pharmaceuticals2026-08-19 11:00 EST

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

TARSTarsus Pharmaceuticals2026-09-04 12:39 EST

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

TARSTarsus Pharmaceuticals2026-09-01 20:30 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Stock data

Close
74.11 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States